TAMPA, Florida. You have probably already heard of the drug Ozempic, used to treat diabetes. But along the way, doctors discovered that it also helped patients lose weight by reducing their cravings. This drug, in high demand, is causing supply shortages around the world. Now, there’s a new warning from the FDA regarding the popular …
(The Hill) The Food and Drug Administration (FDA) approved Eli Lilly’s blockbuster diabetes drug for weight loss management on Wednesday, giving patients another tool and opening the door to potentially using much wider. Formal FDA approval means tirzepatide could be covered by most insurance plans, making it more affordable for millions of patients and likely …
The Food and Drug Administration is investigating several hospitalizations and deaths potentially linked to counterfeit semaglutide drugs, such as Ozempic, according to multiple reports. At least three Americans have been hospitalized after injecting themselves with suspected counterfeit products, CBS News reported. The hospitalizations under investigation are believed to be among 42 cases reported to the …
The Food and Drug Administration on Wednesday has approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that in clinical trials has been shown to help people lose up to 52 pounds in 16 months. Related to Zep is the latest entrant in the field of powerful new drugs that already includes Novo …
At least three Americans were reportedly hospitalized after using suspected counterfeit semaglutide medications, including Novo Nordisk’s diabetes drug Ozempic, according to records released by the Food and Drug Administration. Ozempic and Wegovy, another semaglutide drug from Novo Nordisk, have been in shortage for months amid booming sales for their use in weight loss. These hospitalizations …
In a new study, researchers found that four of the five original studies on the effectiveness of alprazolam (Xanax) did not show it to be better than placebo. Two of the negative studies remain unpublished, while two others were presented as positive upon publication despite the drugs’ failure to beat the placebo. Only one of …
The U.S. Food and Drug Administration (FDA) has approved vonoprazan tablets 10 mg and 20 mg (Voquezna, Phathom Pharmaceuticals) for the cure and maintenance of healing of all grades of erosive esophagitis, also known as erosive gastroesophageal reflux disease (GERD), as well as relief from associated heartburn, the company announced. Vonoprazan, an oral potassium-competitive acid …
Find out what clicks on FoxBusiness.com The Food and Drug Administration (FDA) is warning consumers about more than two dozen eye drops that the agency says could cause eye infections and potentially lead to vision loss. Despite recent warnings, experts say consumers shouldn’t avoid all eye drop products, especially their prescription medications. Instead, consumers should …
The U.S. Food and Drug Administration (FDA) approved Phathom Pharmaceuticals’ vonoprazan (Voquenza) on November 1, 2023 for the treatment of adults with erosive esophagitis (erosive GERD), a gastroesophageal reflux disease. The drug is expected to be commercially available by December 2023. The drug’s approval marks a critical moment for more than 20 million patients suffering …
Stelara is an interleukin-12 and interleukin-23 antagonist used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The original product is available in intravenous and subcutaneous formulations. The FDA has approved Wezlana (ustekinumab-auub), making it the first approval for blockbuster biosimilar drug Stelara (ustekinumab). The agency also granted Wezlana an interchangeability …